| abstract |
The present invention relates to a composition for preventing or treating a TNF-α-related disease, comprising hydroflumethiazide or a pharmaceutically acceptable salt thereof as an active ingredient, and the present invention can effectively inhibit the expression or activity of TNF-α and exhibits an excellent treatment effect compared to methotrexate (MTX) or hydroxychloroquine (HCQ), which are rheumatoid arthritis treatment agents currently on the market, and, thus, can be effectively used for prevention or treatment of a TNF-α-related disease. |